Harrow Announces Commercial Launch Of BYOOVIZ, FDA-Approved Biosimilar Referencing LUCENTISi And Developed By Samsung Bioepis

Harrow (NASDAQ: HROW ), a leading provider of ophthalmic disease management solutions in North America, today announced the commercial launch of BYOOVIZ® (ranibizumab-nuna), an FDA-approved biosimilar referencing LUCENTISi (ranibizumab) and developed by Samsung Bioepis Co., Ltd. The launch follows Harrow's exclusive U.S. commercialization agreement with Samsung Bioepis, one of the world's leading biosimilar developers and manufacturers. Through this partnership, Harrow obtained exclusive U.S. rights to commercialize BYOOVIZ and OPUVIZ® (aflibercept-yszy), an FDA-approved biosimilar referencing EYLEAii (aflibercept), further strengthening the Company's position in the rapidly growing retinal biologics market. BYOOVIZ was approved by the U.S. Food and Drug Administration (FDA) as the first ophthalmology biosimilar in the U.S. for the treatment of patients with Neovascular (Wet...